(1S,5R)-6-azabicyclo<3.2.0>heptan-7-one | 39155-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (1S,5R)-6-azabicyclo<3.2.0>heptan-7-one
• 英文别名: (1S,5R)-6-azabicyclo[3.2.0]heptan-7-one；2-Azabicyclo<3.2.0>heptan-3-on
• CAS: 39155-95-8
• 化学式: C₆H₉NO
• 分子量: 111.144
• InChiKey: AXDBIGNYXNSBHV-CRCLSJGQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1S,5R)-6-azabicyclo<3.2.0>heptan-7-one 在 盐酸 、 水 、 potassium hydrogencarbonate 作用下， 以 水 、 丙酮 为溶剂， 反应 48.0h， 生成 Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid
  参考文献：
  名称：

  Hairpin Folding Behavior of Mixed α/β-Peptides in Aqueous Solution

  摘要：

  The invention of new strategies for the design of protein-mimetic oligomers that manifest the folding encoded in natural amino acid sequences is a significant challenge. In contrast to the a-helix, mimicry of protein beta-sheets is less understood. We report here the aqueous folding behavior of a prototype alpha-peptide hairpin model sequence varied at cross-strand positions by incorporation of 16 different beta-amino acid monomers. Our results provide a folding propensity scale for beta-residues in a protein beta-sheet context as well as high-resolution structures of several mixed-backbone alpha/beta-peptide hairpins in water.

  DOI：

  10.1021/ja2002346
• 作为产物：
  描述：

  N-hydroxymethyl-6-azabicyclo[3.2.0]heptan-7-one 在 甲醇 、 ammonium hydroxide 作用下， 生成 (1S,5R)-6-azabicyclo<3.2.0>heptan-7-one
  参考文献：
  名称：

  Biocatalysis for the preparation of optically active β-lactam precursors of amino acids

  摘要：

  Enantioselective acylation of N-hydroxymethylated beta-lactams in the presence of Pseudomonas sp. lipase afforded optically active precursors for the preparation of (1R,2S)- and (1S,2R)-2-aminocyclopentane- and (1R,2S,3R,4S)- and (1S,2R,3S,4R)-3-aminobicyclo[2.2.1]heptanecarboxylic acids. Due to the high enantioselectivity (E = 90 and 62) and in order to minimize the enzymatic hydrolysis of the acylated products back to the starting alcohol, the reactions were performed in acetone. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00214-5

文献信息

• Arylethynyl derivatives
  申请人：Green Luke

  公开号：US20110251169A1

  公开（公告）日：2011-10-13

  The present invention relates to ethynyl compounds of formula I wherein R1, R2, R2′, R3, R3′, R4, R4′, U, V, W, Y, m, and n are as defined herein and to a pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof. Compounds of formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

  本发明涉及式I的乙炔基化合物，其中R1、R2、R2′、R3、R3′、R4、R4′、U、V、W、Y、m和n如本文所述，以及药用可接受的酸加成盐，或其对映体和/或光学异构体和/或立体异构体的相应外消旋混合物。式I的化合物是代谢型谷氨酸受体5亚型（mGluR5）的变构调节剂。
• 2,4-diamino-pyrimidines as aurora inhibitors
  申请人：Zahn Karl Stephan

  公开号：US20070032514A1

  公开（公告）日：2007-02-08

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 至 R 3 如权利要求书中所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物组合物。
• Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
  申请人：Levin I. Jeremy

  公开号：US20060211730A1

  公开（公告）日：2006-09-21

  This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.

  这项发明提供了具有结构的Formula I的化合物，这些化合物在治疗由TNF-α介导的疾病或紊乱方面非常有用，如关节炎（类风湿关节炎（RA），幼年RA，银屑病性关节炎，骨关节炎等），肿瘤转移，组织溃疡，异常伤口愈合，牙周病，骨病，糖尿病（胰岛素抵抗）和HIV感染，强直性脊柱炎，银屑病，败血症，多发性硬化，克罗恩病，退行性软骨丢失，哮喘，特发性肺纤维化，血管炎，系统性红斑狼疮，肠易激综合征，急性冠状动脉综合征，丙型肝炎，虚弱，慢性阻塞性肺病，中风或2型糖尿病的缓解症状。该发明还提供了使用这些化合物的方法。
• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• Antimicrobial N-acyl-2-azetidinones
  申请人：THE UPJOHN COMPANY

  公开号：EP0232017A1

  公开（公告）日：1987-08-12

  The present invention provides novel compositions of matter and processes for their preparation. Particularly, the present invention relates to novel monocyclic β-lactams of formula I, having a carbonyl group, other than a negatively charged group, attached to the N-1 position. The compounds are useful as antimicrobial agents or as intermediates thereto. The present invention also provides a novel process for making these compounds which utilizes palladium (O)-­catalyzed carbonylation of an appropriate 2-bromo-1-propen-3-yl amine and novel intermediates prepared by this process.

  本发明提供了一种新的物质组合物及其制备过程。特别是，本发明涉及一类新型的单环β-内酰胺类化合物，其具有一个羰基团，而不是一个负电荷团，连接到N-1位置。这些化合物可用作抗菌剂或作为其前体。本发明还提供了一种制造这些化合物的新过程，该过程使用钯(0)催化的2-溴-1-丙烯-3-基胺的羰基化反应，以及通过该过程制备的新型中间体。